Jazz Pharmaceuticals Reports Record $4.3 Billion Revenue in 2025, Prepares Zanidatamab Launch for Gastroesophageal Cancer
核心洞察
Jazz Pharmaceuticals achieved record total revenues of $4.3 billion in 2025, representing 5% year-over-year growth and marking the company's 21st consecutive year of top-line growth.
The company plans to complete a supplemental biologics license application submission for zanidatamab in first-line HER2 (搜索)+ gastroesophageal adenocarcinoma (搜索) in Q1 2026, with potential launch in the second half of 2026.
Xywav generated $1.7 billion in revenue with 12% year-over-year growth, while Epidiolex achieved blockbuster status with $1.1 billion in sales and 9% growth.
Jazz Pharmaceuticals plc reported record financial results for 2025, achieving $4.3 billion in total revenues with 5% year-over-year growth, while positioning itself for a significant regulatory milestone with its HER2 (搜索)-targeted cancer therapy zanidatamab. The Dublin-based biopharmaceutical company announced plans to complete a supplemental biologics license application (sBLA) submission for zanidatamab in first-line HER2+ gastroesophageal adenocarcinoma (搜索) (GEA) during the first quarter of 2026.
Strong Performance Across Key Franchises
Jazz's neuroscience portfolio demonstrated robust growth, with Xywav (calcium, magnesium, potassium, and sodium oxybates) generating $1.7 billion in net product sales, representing 12% year-over-year growth. The sleep disorder treatment served approximately 16,175 active patients at the end of the quarter, including 10,950 narcolepsy (搜索) patients and 5,225 idiopathic hypersomnia (搜索) patients, with approximately 500 net patient additions in the fourth quarter alone.
Epidiolex/Epidyolex (cannabidiol) achieved blockbuster status in 2025 with net product sales of $1.1 billion, marking 9% year-over-year growth. The epilepsy (搜索) treatment contributed significantly to the company's total neuroscience revenue of $3.1 billion, which increased 6% compared to 2024.
Zanidatamab Positioned as Practice-Changing Therapy
The company's oncology pipeline received a significant boost from Phase 3 HERIZON-GEA-01 trial results, which Jazz believes position zanidatamab as the HER2 (搜索)-targeted agent of choice in HER2+ first-line gastroesophageal adenocarcinoma (搜索), regardless of PD-L1 status. Rob Iannone, M.D., M.S.C.E., executive vice president and chief medical officer, stated that the results "firmly position zanidatamab as the HER2-targeted agent of choice, with the potential to reshape first-line treatment for HER2+ metastatic GEA patients."
The FDA granted Breakthrough Therapy designation for zanidatamab's development in patients with HER2 (搜索)+ unresectable locally advanced or metastatic GEA. Jazz has submitted the HERIZON-GEA-01 data for potential inclusion in National Comprehensive Cancer Network (NCCN) guidelines and expects a potential launch in first-line HER2+ GEA during the second half of 2026.
Expanding Oncology Portfolio
Jazz's oncology franchise generated $1.1 billion in net product sales for 2025, representing 2% growth compared to 2024. The portfolio expansion included successful launches of newly acquired therapies. Modeyso (搜索) (dordaviprone), launched in August 2025 following the Chimerix acquisition, achieved $48 million in sales since launch, with $37 million generated in the fourth quarter alone. The treatment targets H3 K27M-mutant diffuse midline glioma (搜索), a rare pediatric brain cancer.
Ziihera (zanidatamab-hrii) generated $25 million in net product sales for biliary tract cancer (搜索) in 2025, following its December 2024 launch. The company is also advancing the EmpowHER-BC-303 trial in metastatic breast cancer (搜索) patients previously treated with or intolerant to trastuzumab deruxtecan, with enrollment expected to complete in the first half of 2027 and top-line results anticipated in late 2027 or early 2028.
Financial Outlook and Strategic Direction
Jazz projects 2026 total revenues between $4.25 to $4.50 billion, with double-digit growth expected across combined epilepsy (搜索) and oncology franchises. The company generated $1.4 billion in cash from operations during 2025, maintaining a strong balance sheet with $2.4 billion in cash, cash equivalents, and investments as of December 31, 2025.
"2025 was an exceptional year for Jazz, representing our 21st consecutive year of top-line growth and underscoring our commitment to operational excellence as we deliver meaningful innovation for patients," said Renee Gala, president and chief executive officer. The company continues to pursue a corporate development strategy aligned with its rare disease focus, recently appointing Tom Riga as chief business officer to accelerate these efforts.
Research and Development Progress
Jazz's research and development expenses decreased in 2025 compared to 2024, primarily due to lower clinical study costs related to zanidatamab resulting from the timing of clinical trial activities, and the completion of JZP258 (XYLO/DUET) trials in the first half of 2025. The company discontinued its JZP385 program for essential tremor, while adding costs related to Modeyso (搜索) and increased personnel following the Chimerix acquisition.
The company's pipeline advancement includes multiple registrational trials of zanidatamab underway, supporting a broad development program designed to maximize patient impact across various HER2 (搜索)+ cancer indications. Jazz believes these results not only highlight zanidatamab's potential in GEA but also de-risk clinical trials in additional indications, including HER2+ metastatic breast cancer (搜索).